Moderna vaccine reduced viral load and protected against SARS-CoV-2 variants in new phase 3 trial
Coronavirus research has shown that higher viral loads are associated with severe COVID-19 infection. But new results from the phase III Coronavirus Efficacy (COVE) clinical trial find the Moderna vaccine reduces severe acute respiratory coronavirus 2 (SARS-CoV-2) viral load and viral shedding. // 30.9.2021
The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmission
Background Pre-Delta, vaccination reduced transmission of SARS-CoV-2 from individuals infected despite vaccination, potentially via reducing viral loads. While vaccination still lowers the risk of infection, similar viral loads in vaccinated and unvaccinated individuals infected with Delta question how much vaccination prevents onward transmission. // 29.9.2021
Model predicts SARS-CoV-2 spread in vaccinated vs. unvaccinated populations
A modeling study led by Kuan-lin Huang of the Icahn School of Medicine at Mount Sinai in New York suggests that getting vaccinated and taking preventative measures such as social distancing and mask-wearing is the most effective way to curb the spread of severe acute respiratory coronavirus 2 (SARS-CoV-2).// 29.9.2021
How effective are COVID-19 vaccines against SARS-CoV-2 variants of concern?
The authors from this paper performed a systematic review and meta-analysis evaluating vaccine effectiveness from RCTs and observational studies. // 29.9.2021
COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection
In a study conducted at the European Institute of Oncology, scientists have found that the risk and duration of SARS-CoV-2 infection reduced significantly after COVID-19 vaccination. // 28.9.2021
New research shows certain groups of vaccinated people could still be at risk from COVID-19
An actuary from the Government Actuary's Department (GAD) is one of a group of scientists, clinicians and cross-government analysts who have published new research on further effects of COVID-19.
Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant
Researchers in Japan have conducted a study showing that the vaccine developed by Pfizer-BioNTech to protect against coronavirus disease 2019 (COVID-19) seems to be adequately effective against the B.1.621 (mu) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). // 27.9.2021
mRNA COVID vaccines prove effective in the elderly
Coronavirus disease 2019 (COVID-19) proved extremely difficult to control once it entered a country – while there were a few success stories such as New Zealand, most countries ended up resorting to lengthy and economically painful lockdowns, among other restriction measures. // 27.9.2021
Study shows prior COVID-19 and vaccination protects elderly against variants
In order to qualify the risk posed to the elderly, researchers from MUSE University in France began to investigate data from nursing homes that had faced outbreaks from variants of concern. Their work can be found on the medRxiv* preprint server while awaiting peer review. // 27.9.2021
COVID-19 vaccine effectiveness barely affected by Delta variant, research suggests
Has the Delta (B.1.617.2) variant reduced vaccine effectiveness? If you ask Ian Foster of Argonne National Laboratory and colleagues, the answer is not really. New research published in the preprint medRxiv* server suggests vaccines approved in the United States are stable and well-performing. // 27.9.2021
Varying immune responses after single dose of Pfizer and AstraZeneca COVID-19 vaccines
A new preprint describes the significant variation in the early immune response elicited by two of the earliest vaccines to gain emergency authorization against COVID-19. // 23.9.2021
Researchers encourage longer dosing intervals for Pfizer-BioNTech’s COVID-19 vaccine
Researchers in Canada, Italy, and the United States have encouraged extending the interval time between two doses of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine among individuals who have not previously been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). // 22.9.2021
mRNA-based and adenoviral vector-based COVID-19 vaccines elicit diverse humoral immunity
Scientists from the USA have recently compared the dynamics of humoral and cellular immune responses induced by mRNA-based and adenoviral vector-based coronavirus disease 2019 (COVID-19) vaccines. The findings reveal a difference in humoral immune responses. // 23.9.2021
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study
COVID-19 vaccine effectiveness against SARS-CoV-2 variants
A commentary published in the journal Cell summarizes international data on vaccine effectiveness against new severe acute respiratory coronavirus 2 (SARS-CoV-2) variants. Evidence shows that the currently approved vaccines continue to be effective in preventing severe and symptomatic illness — even with the widely circulating Delta variant. // 21.9.2021
Early data from Israel’s Ministry of Health drew concerns of vaccines being less effective against symptomatic Delta infection. However, the researchers note this data may have been unreliable. “…further preprint published research did not report effectiveness figures against symptomatic infection as symptoms reporting was not reliable in the national database. Vaccine effectiveness against infection is much harder to measure as these estimates are affected by various biases such as testing criteria, behavior, exposure risk, immunity status of the population, and community prevalence.”
Dutch study shows COVID vaccines 97% effective in preventing ICU admission
Vaccinations help keep people out of the hospital, according to a new preprint medRxiv* study from researchers at the University of Amsterdam and the National Institute for Public Health and the Environment (RIVM) in the Netherlands. // 21.9.2021
.jpg?width=92&height=&ar=&mode=&format=avif&dpr=2)
.jpg?width=92&height=&ar=&mode=&format=avif&dpr=2)
.jpg?width=92&height=&ar=&mode=&format=avif&dpr=2)
-1.jpg?width=92&height=&ar=&mode=&format=avif&dpr=2)
.jpg?width=92&height=&ar=&mode=&format=avif&dpr=2)
.jpg?width=92&height=&ar=&mode=&format=avif&dpr=2)
.jpg?width=92&height=&ar=&mode=&format=avif&dpr=2)
